Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,617.10 -329.83 (-0.85%) Hang Seng
19,195.60 -25.02 (-0.13%) FTSE 100
8,392.49 -23.96 (-0.28%) Bitcoin USD
69,996.03 -975.61 (-1.37%) CMC Crypto 200
1,498.53 -27.89 (-1.83%)
Psyence Biomedical Ltd. (PBM)
Pre-market:
| Previous close | 0.8650 |
| Open | 0.8880 |
| Bid | 0.7868 x 100 |
| Ask | 0.8920 x 100 |
| Day's range | 0.8213 - 0.8880 |
| 52-week range | 0.5140 - 14.5500 |
| Volume | |
| Avg. volume | 3,691,790 |
| Market cap | 11.366M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21, 2024. For more information, or to register: https://allianceg.com/events/. About Psyence Biomed Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, is the world’s first life science biotechnology comp
- GlobeNewswire
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p. The randomized, double-blind, placebo-con
- GlobeNewswire
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that its Australian subsidiary, Psyence Australia Pty Ltd ("Psyence Australia"), has entered into a partnership with Fluence, a global leader in profess
